bioRxivCancer Biology
Regulation of eIF4F complex by the peptidyl prolyl isomerase FKBP7 in taxane-resistant prostate cancer
M. F. GARRIDO, N. J. MARTIN, C. GAUDIN, F. Commo, N. AL NAKOUZI, L. FAZLI, E. DEL NERY, J. Camonis, F. Perez, S. LERONDEL, A. LE PAPE, H. ABOU-HAMDAN, M. Gleave, Y. Loriot, L. DESAUBRY, s. VAGNER, K. FIZAZI, A. CHAUCHEREAU
Abstract
Targeted therapies that exploit the signaling pathways involved in prostate cancer are required to overcome chemoresistance and improve treatment outcomes for men. Molecular chaperones play a key role in the regulation of protein homeostasis and are potential targets to alleviate chemoresistance. Using image-based high content siRNA functional screening based on a gene expression signature, we identified FKBP7, a molecular chaperone overexpressed in docetaxel-resistant and in cabazitaxel-resistant prostate cancer cells. FKBP7 was upregulated in human prostate cancers and correlated with the recurrence in patients receiving Docetaxel. FKBP7 silencing showed that FKBP7 is required to maintain the growth of chemoresistant cell lines and of chemoresistant tumors in mice. Mass spectrometry analysis revealed that FKBP7 interacts with the eIF4G component of the eIF4F translation initiation complex to mediate survival of chemoresistant cells. Using small molecule inhibitors of eIF4A, the RNA helicase component of eIF4F, we were able to overcome docetaxel and cabazitaxel resistance.
- organism: human
- assay: proteomics
- research focus: drug response / drug discovery
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Cytoplasmic FKBP7 reflux sustains NFE2L1 levels in an adaptive response to chemotherapy in prostate cancer cells
Luce Dreno, Farès Ousalem, … Anne Chauchereau·bioRxiv·Oct 14, 2026
- Exploiting Epigenetic Targets to Overcome Taxane Resistance in Prostate Cancer
B. Cevatemre, I. Bulut, … C. Acilan Ayhan·bioRxiv·Aug 10, 2023
- FOXJ1 mediates taxane resistance through regulation of microtubule dynamics
Fang Xie, Ada Gjyrezi, … Steven P. Balk·Nature CommunicationsPeer-reviewed·Feb 14, 2026
- The ERK1/2-Elk1, JNK-cJun, and JAK-STAT Transcriptional Axes as Potential Bortezomib Resistance Mediators in Prostate Cancer
G. Kalampounias, K. Zafeiropoulou, … P. Katsoris·bioRxiv·Apr 15, 2024
- SRPK1 is a determinant of chemoresistance to Docetaxel in prostate cancer
Duygu Duzgun, William Read, Sebastian Oltean·bioRxiv·Sep 17, 2026
- Pre-existing cell subpopulations in primary prostate cancers display surface fingerprint of docetaxel-resistant cells
S. Drapela, B. Kvokackova, … K. Soucek·bioRxiv·Jan 28, 2021